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Abstract
AIM: While colorectal cancer (CRC) is an ideal target for
population screening, physician and patient attitudes
contribute to low levels of screening uptake. This study
was carried out to find feasible economic strategies to
improve the CRC screening compliance in Korea.
METHODS: The natural history of a simulated cohort of
50-year-old Korean in the general population was modeled
with CRC screening until the age of 80 years. Cases of
positive results were worked up with colonoscopy. After
polypectomy, colonoscopy was repeated every 3 years.
Baseline screening compliance without insurance coverage
by the national health insurance (NHI) was assumed to
be 30%. If NHI covered the CRC screening or the
reimbursement of screening to physicians increased, the
compliance was assumed to increase. We evaluated 16
different CRC screening strategies based on Markov model.
RESULTS: When the NHI did not cover the screening and
compliance was 30%, non-dominated strategies were
colonoscopy every 5 years (COL5) and colonoscopy every
3 years (COL3). In all scenarios of various compliance
rates with raised coverage of the NHI and increased
reimbursement of colonoscopy, COL10, COL5 and COL3
were non-dominated strategies, and COL10 had lower or
minimal incremental medical cost and financial burden
on the NHI than the strategy of no screening. These results
were stable with sensitivity analyses.
CONCLUSION: Economic strategies for promoting
screening compliance can be accompanied by expanding
insurance coverage by the NHI and by increasing
reimbursement for CRC screening to providers. COL10
was a cost-effective and cost saving screening strategy
for CRC in Korea.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Korea is known to be a low-risk area for colorectal cancer
(CRC), but the incidence has been rapidly increasing during
the last decade. From 1987 to 1996, the age-standardized
mortality rate for CRC has roughly doubled from 8.7 to
16.5 per 100 000 for men and 6.3 to 14.3 per 100 000 for
women[1]. Screening for CRC reduces mortality through
detection of malignancy at an earlier, more treatable stage
as well as by identification and removal of precursor lesion,
the adenomatous polyp [2] .  Recent panel in Korea
recommends that an average-risk individual should begin
CRC screening at the age of 50 with one of the two following
guidelines[3]: 1. Colonoscopy (COL) every 5-10 years. 2.
Flexible sigmoidoscopy (SIG) and double-contrast barium
enema (DCBE) every 5 years.
However, these recommendations condoned by expert
panels, were not based on economic evaluation. CRC
screening tests vary considerably in terms of  their
performance characteristics, complication rates, acceptability
and cost. Especially the cost structure for reimbursement
of CRC screening and treatment in Korea is different from
that in other countries. Colonoscopy, sigmoidoscopy and
DCBE for CRC screening are not covered by national health
insurance (NHI) scheme in Korea. Previous studies have
demonstrated that out-of-pocket payment was a barrier to
cancer screening and health insurance was an important
determinant of  the utilization of  cancer screening[4,5]. In
addition, physician’s noncompliance with screening
recommendation was known to be a major barrier to
effective CRC control[6]. Perceived inadequacy of the
reimbursement of colonoscopy or sigmoidoscopy was one
of the factors affecting physician’s compliance[7].
To improve the physician and patient compliance for
CRC screening, some reports have demonstrated that the
third-party payer should remove financial barriers by
providing insurance coverage and raising reimbursement
of CRC screening to physicians[8]. However, Korean NHI
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has experienced an annual deficit since 1997 and fiscal
stability is a major concern[9]. At the current status, new
national policy on screening should not put financial burden
on the Korean NHI system and needs to take into account
economic consequences.
To suggest a feasible economic model to improve the
compliance by raising insurance coverage and reimbursement
without increasing financial burden on the NHI, we
constructed a decision-analytic model to evaluate the cost-




The natural history of a simulated cohort of 50-year-old
Koreans in the general population was modeled with and
without CRC screening until the age of 80 years (Figure 1).
We evaluated 16 different screening strategies with Markov
model. Persons representative of the 50-year-old Korean
population were placed into health states defined by the
presence or absence of a polyp or cancer (early or advanced).
Cases of positive screening test results were worked up
with a colonoscopy, and individuals diagnosed with polyp
underwent polypectomy. Colonoscopy was repeated every
3 years for surveillance after polypectomy[10]. The probability
of perforation was assigned to DCBE, SIG, COL and
polypectomy[11-13]. Mortality caused by the risk of perforation
was assumed to be 0.02%[13,14].
Our main outcome measures were discounted lifetime
costs, life expectancy, lifetime NHI’s financial burden and
incremental cost-effectiveness ratio (ICER), which were
compared for 16 different CRC screening strategies.
Incremental cost-effectiveness analysis was performed by
ranking the 16 strategies in the order of increasing
effectiveness. After eliminating strategies, that were more
or equally costly and less effective than a competing strategy
(i.e., ruled out by simple dominance), we calculated the ICER
for each strategy (additional cost divided by additional
benefit) compared with the next least expensive strategy. If
a strategy was less effective and had a higher ICER than
another strategy, it was ruled out by extended dominance[15].
Strategies exhibiting extended dominance were eliminated
from the rank-ordered list, and ICERs of the remaining
strategies were recalculated. Future costs and life-years were
discounted at an annual rate of 3%. The model was
programmed in DATA Pro 4.0 software (TreeAge Software
Inc., Williamstown, MA).
Clinical data
Natural history of  colorectal polyps and cancer  Table 1
showed selected parameter estimates. We estimated the age-
specific prevalence of adenomatous polyps from previous
studies in Korea[3,16]. The incidence of polyp is assumed to
be constant calibrated with the two prevalence rates between
age 50 and 65. The probability of  transformation from
polyp to cancer was estimated from the study of patients
who refused the resection of  polyp[17]. We assumed that the
longer the duration of polyp, the greater the probability of
transformation from polyp to cancer.
Figure 1  Markov model of colorectal cancer screening. The ovals represent Markov states in which patients remain for at least full 1-year
cycle. The squares represent intermediate states of screening procedures, in which patients may enter and leave during one cycle. The
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We defined early stage cancer as modified Duke’s stage
A and advanced stage as modified Duke’s stage B-D[18,19].
The latent period between early stage and advanced stage
was assumed to be 2 years[14]. The stage-specific CRC
mortality was applied uniformly to all malignancies, regardless
of the means of detection (by symptoms or screen) or the
state of detection (diagnose vs undiagnose cancer). Five-
year survival rates from previous studies were used for the
yearly probability of dying from CRC based on the stage
and number of years with cancer[20,21]. Age-specific mortality
from other causes was estimated, based on the above source
combined with statistics published by the National Center
for Health Statistics[22].
Cost
We obtained the data on the costs of  CRC treatment by
stage and time period from the National Health Insurance
Corporation (social insurer of the NHI with a universal
coverage of population)[23]. However, the co-payment that
patients pay at the point of  service amounts to about 50%
of the total medical expenses of CRC treatment in Korea[3,9].
Therefore, the total medical cost of CRC treatment was
assumed to be twice the expense that the NHI reimburses.
Costs of screening test were obtained from the fee schedule
of the National Health Insurance Corporation (the NHI
of Korea has a fee schedule applied to all insured services)[24].
Compliance and screening cost
Compliance rates of 50-70% were obtained in the optimized
setting of clinical trials of CRC screening[2]. However,
colonoscopy, sigmoidoscopy and DCBE for CRC screening
are not covered by the NHI in Korea. Therefore, the
compliance is likely to be lower than that in other countries
where CRC screening is covered by health insurance. At
each particular screening event without NHI benefit
coverage, we assumed that 30% of population underwent
the initial screening test, independent of whether they were
compliant with past tests. The compliance of follow-up or
surveillance colonoscopy was assumed to be 20% higher
than that of the initial screening.
If the NHI covered the CRC screening or the amount
of reimbursement for screening to providers increased, the
compliance was assumed to increase. If the NHI covered
50% and 100% of screening cost, the compliance was
assumed to be 15% and 30% higher than that in case of
non-coverage respectively, by reducing the financial barrier
of patients. The Korean Medical Association had insisted
that current reimbursement of colonoscopy to physicians
was too low and the appropriate level should be 60% higher
than the current level [25]. An increase in colonoscopy
reimbursement, to 60% higher than the current level, was
assumed to lead to 10% increase in the compliance due to
financial incentives for physicians.
Table 1  Summary of assumption
Parameter Base case value Reference
Sensitivity and specificity Sensitivity of FOBT for polyps/cancer 0.1/0.5 [15], [28], [29], [30]
of screening and diagnosis Sensitivity of colonoscopy for polyps/cancer 0.85/0.97 [2], [31], [32]
Sensitivity of colon study for polyps/cancer 0.5/0.8 [2], [33], [34]
Sensitivity of sigmoidoscopy for polyps/cancer 0.67 [1], [2], [31], [32]
Specificity of FOBT 0.9 [15], [28], [29], [30]
Specificity of colonoscopy 1 [2], [31], [32]
Specificity of colon study 0.9 [2], [33], [34]
Specificity of sigmoidoscopy 1 [2], [31], [32]
Natural history of Prevalence of polyps at age 50 0.25 [13], [36]
polyp/cancer  sequence Annual polyp incidence rate 0.005 [13], [36]
Percent of cancers originating as polyps 100% [37], [38]
Annual cancer incidence of polyp whose duration is below 5 yr 0.005 [17], [39], [40], [41]
Annual cancer incidence of polyp whose duration is from 5 to 10 yr 0.01 [17], [39], [40], [41]
Annual cancer incidence of polyp whose duration is above 10 yr 0.016 [17], [39], [40], [41]
Dwelling time of cancer in early stages 2 yr [29], [42]
Percent of cancers detected in early stages with no screening 5% [21]
Five-year all cause survival for early cancer 90% [21], [20]
Five-year all cause survival for advanced cancer 54% [20], [21], [23]
Polyp recurrence rate after polypectomy in the first year 0.11 [2], [3]
Polyp recurrence rate after polypectomy thereafter 0.03 [2], [3]
Complications and Rate of perforation of colon in colonoscopy 0.002 [12], [13]
unintended consequences Rate of perforation of colon in polypectomy 0.004 [12], [13]
Rate of perforation from sigmoidoscopy 0.0001 [12], [13]
Rate of perforation from colon study 0.00005 [7]
Death rate from perforated colon 0.002 [16], [17]
 Cost (won1) Sigmoidoscopy 26 620 [24]
Colonoscopy 52 560 [24]
Colon study 58 600 [24]
FOBT 2 290 [24]
Polypectomy 134 600 [24]
Biopsy 24 160 [24]
Treatment of early cancer for first year 5 150 000 [3], [17], [23]
Treatment of advanced cancer for first year 10 300 000 [3], [17], [23]
Treatment of cancer after first year 2 164 000 [3], [17], [23]
Treatment of colonic perforation 3 000 000 [3]
1Exchange rate: 1200 Korean won for one US dollar.
As there were no data available on the compliance
changes resulting from the change in insurance coverage or
reimbursement level, we performed sensitivity analysis to
assess the stability of the results to plausible ranges of
compliances. The compliance rate was set to vary from
10% lower to 10% higher than the baseline value.
RESULTS
In the base-case analysis at 30% screening compliance
without NHI coverage, all screening strategies extended life
expectancy. And the strategies which were not ruled out by
simple dominance or extended dominance (non-dominated
strategies) were colonoscopy every 5 years (COL5) and
colonoscopy every 3 years (COL3). The screening strategies
with colonoscopy or sigmoidoscopy showed lower total
medical cost and lower financial burden on the NHI than
the strategy of  no screening (Table 2).
If the NHI covered 50% of the screening cost and the
screening compliance was 45%, non-dominated strategies
were colonoscopy every 10 years (COL10), COL5 and
COL3. As the coverage of NHI increased, the financial
burden on NHI increased. Nevertheless, the financial burden
on the NHI associated with COL10 was smaller than that
associated with no screening (Table 3). In the case that NHI
covered 100% of screening cost, non-dominated strategies
Table 2  Cost-effectiveness of 16 strategies of colorectal screening among Korean adults without NHI coverage (NHIa coverage = 0%,
screening compliance = 30%, follow-up compliance = 50%)
       Strategy               Lifetime cost per         Life expectancy,     Incremental Incremental days             Lifetime financial                Incremental C/E3, won2
(abbreviation)                 person, won2   cost per day    person, won2     of life gained          burden of NHI1, won2                    per life-year gained
COL5 311 682       6 176.1 139 043
COL3 313 877       6 181.1            2 195              5.0 128 757            160 965
COL10 321 407       6 171.7            7 530 151 394        (Dominated)4
COL at 55 336 367       6 167.9          22 490 164 547        (Dominated)
SIG3 346 903       6 172.4          33 026 155 607        (Dominated)
SIG5 352 290       6 167.9          38 413 164 996        (Dominated)
SIG10 356 222       6 165.8          42 345 171 689        (Dominated)
SIG at 55 359 939       6 164.4          46 062 177 231        (Dominated)
SIG5+DCBE5 368 560       6 168.1          54 683 165 557        (Dominated)
No screening 370 726       6 161.9          56 849 185 236        (Dominated)
FOBT2 375 772       6 165.5          61 894 187 015        (Dominated)
FOBT1+SIG5 384 709       6 169.7          70 832 187 443        (Dominated)
FOBT1 387 912       6 168.1          74 035 192 309        (Dominated)
DCBE10 390 767       6 164.1          76 890 177 826        (Dominated)
DCBE5 410 554       6 165.3          96 677 174 392        (Dominated)
DCBE3 435 775       6 169.3       121 898 169 661        (Dominated)
COL, colonoscopy; SIG, sigmoidoscopy; DCBE, double contrast barium enema; FOBT, fecal occult blood test. Ellipses indicate no data (incremental days or life
gained and incremental CE ratio were not calculated for these strategies because they were dominated or extended dominated). 1National Health Insurance of
Korea. 2Exchange rate: 1200 Korean won for one US dollar. 3Incremental CE ratio (won/year) = Incremental cost per person/Incremental days of life gained×365
d. 4Dominated strategy is a strategy that is more or equally costly and less effective than a competing strategy.
Table 3  Cost-effectiveness of 16 strategies of colorectal screening among Korean adults with changing NHI1 coverage and compliance
      Strategy                    Lifetime                     Lifetime                     Incremental Strategy              Lifetime cost per          Lifetime             Incremental
(abbreviation)                     cost per             financial burden         C/E3, won2 per     (abbreviation)           person, won2        financial burden          C/E3, won2 per
              person, won2                      of NHI1, won2              life-year gained               of NHI1, won2         life-year gained
       NHI1 coverage = 50%        NHI1 coverage = 100%
Screening compliance = 45%, Screening compliance = 60%,
Follow-up compliance = 65% Follow-up compliance = 80%
COL10 310 354 178 233 COL10 307 395 226 848
COL5 311 640 188 051 93 440 COL at 55 308 933 192 405           (Dominated)
COL at 55 321 624 172 824 (Dominated)4 SIG5 316 541 235 951           (Dominated)
SIG3 328 365 197 511 (Dominated) SIG10 321 728 214 095           (Dominated)
SIG5 332 244 191 881 (Dominated) SIG3 323 691 261 056 (Extended Dominated)5
COL3 336 101 207 072 2 113 350 COL5 325 435 267 054               1 371 670
SIG10 339 760 186 587 (Dominated) SIG at 55 330 560 191 573           (Dominated)
SIG at 55 347 179 181 334 (Dominated) FOBT2 370 827 216 521           (Dominated)
SIG5+DCBE5 369 225 213 205 (Dominated) No screening 370 968 185 809           (Dominated)
No screening 370 847 185 499 (Dominated) COL3 374 192 323 357               5 656 770
FOBT2 373 988 208 794 (Dominated) FOBT1+SIG5 382 870 277 687           (Dominated)
FOBT1+SIG5 380 512 238 067 (Dominated) SIG5+DCBE5 383 934 303 581           (Dominated)
FOBT1 388 456 234 316 (Dominated) FOBT1 389 668 248 595           (Dominated)
DCBE10 394 938 209 420 (Dominated) DCBE10 397 017 260 523           (Dominated)
DCBE5 420 550 229 974 (Dominated) DCBE5 429 376 316 022           (Dominated)
DCBE3 455 758 255 914 (Dominated) DCBE3 478 144 384 805           (Dominated)
COL, colonoscopy; SIG, sigmoidoscopy; DCBE, double contrast barium enema; FOBT, fecal occult blood test. 1National Health Insurance of Korea. 2Exchange rate:
1 200 Korean won for one US dollar. 3Incremental CE ratio (won/year) = Incremental cost per person/incremental days of life gained×365 d. 4Dominated strategy
is a strategy that is more or equally costly and less effective than a competing strategy. 5Extended dominated: Extended dominated strategy is a strategy which
is less effective and had a higher ICER than another strategy.
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were COL10, COL5 and COL3, but theses strategies showed
greater financial burden on the NHI than the strategy of
no screening did (Table 3).
When the reimbursement of colonoscopy was 60%
higher than the current level, along with 50% coverage of
screening cost by the NHI and the compliance rate of 55%,
non-dominated strategies were COL at age 55, COL10,
COL5 and COL3. Total medical costs of  COL at age 55
and COL10 were less than that associated with no screening.
In addition, the NHI’s financial burden in case of COL at
55 was lower than that of no screening, and COL10 had
relatively low incremental burden on the financial status of
the NHI (Table 4).
Results of sensitivity analyses consistently showed the
dominance of colonoscopy. In all cases, COL10, COL5
and COL3 were non-dominated strategies. When the
reimbursement of colonoscopy was 60% higher than the
current level, along with NHI’s 50% coverage of screening
cost and the compliance rate of 65%, COL10 had slightly
higher total medical cost than no screening. In other cases,
total medical cost of COL10 was lower than that of no
screening, and NHI’s financial burden associated with
COL10 was lower or slightly higher than that of no
screening. In all scenarios of various compliance rates,
COL10, COL5 and COL3 were non-dominated strategies,
and COL10 had lower or minimal incremental total medical
cost and NHI’s financial burden than the strategy of  no
screening.
DISCUSSION
We compared 16 strategies for CRC screening, varying in
the level of insurance coverage and reimbursement of
colonoscopy by NHI to providers. In all scenarios, COL
every 10 years, 5 years and 3 years were not ruled out by
either simple or extended dominance, and COL every 10 years
was associated with lower total medical cost than the strategy
of no screening.
Public awareness of the importance of CRC screening
is increasing although the rate of screening remains low[8].
Previous studies have shown that the cost was a barrier to
cancer screening[4,26]. Removing the financial barrier by
providing insurance coverage is one of the effective methods
to raise the screening compliance, but the financial burden
on the NHI can be increasing as well. In other countries,
screening for CRC usually leads to greater life expectancy
but is more costly than no screening. Interestingly, in our
study of Korea, COL every 10 years has lower total medical
cost than the case of no screening. This difference might
be due to the difference in cost structure. In the US,
published cost estimates for the medical care of patients
with CRC range from $25 000 to $45 000 and the cost of
COL is approximately $1 000[14]. In Korea, the cost estimate
of CRC treatment in the first year ranges from $5 000 to
$10 000 and the cost of COL was approximately $50[23,24].
The ratio of treatment cost to COL cost ranges from 25:1
to 45:1 in the US and 100:1 to 200:1 in Korea. Since the
cost of COL is relatively low in Korea, the screening is
more cost-effective than in the US.
In Korea, the government started the national cancer-
screening program (NCSP) in 1999, which included CRC
screening in 2004. The government covers 50% of the
screening cost for the insured and 100% for the low-income
people. The primary method for CRC screening in NCSP
is FOBT. Our study shows that the strategy of  ‘FOBT
annually’ costs more and carries heavier burden on NHI
than the strategy of  no screening, while COL every 10 years
is less costly than no screening. These results suggest that
COL every 10 years can be recommended as a primary
screening strategy for CRC in NCSP. However, if  COL is
to be promoted as a screening tool, there must be sufficient
manpower to deliver colonoscopy to the public. Unfortunately,
Table 4  Cost-effectiveness of 16 strategies of colorectal screening among Korean adults with raising reimbursement of colonoscopy to 60%
higher than current level (Cost of colonoscopy = 85 000 won1, NHI2 coverage = 50% screening compliance = 55%, follow-up compliance = 75%)
       Strategy             Lifetime cost per            Life            Lifetime financial  Incremental C/E3, won1
(abbreviation)                                    person, won1                      expectancy, day                            burden of NHI2, won1                        per life-year gained
COL at 55 339 486           6 173.1 184 815
SIG at 55 353 851           6 169.0 182 912             (Dominated)4
COL10 362 230           6 179.1 208 801                 1 401 600
SIG10 364 257           6 173.3 192 838             (Dominated)
No screening 371 238           6 161.9 185 704             (Dominated)
SIG5 377 039           6 178.0 201 390             (Dominated)
FOBT2 384 067           6 170.8 219 587             (Dominated)
SIG3 399 919           6 183.0 210 271 (Extended dominated) 5
COL5 402 824           6 184.0 238 433                 2 992 270
FOBT1 409 771           6 176.2 254 521             (Dominated)
DCBE10 410 690           6 169.1 221 430             (Dominated)
FOBT1+SIG5 426 305           6 180.8 262 952             (Dominated)
SIG5+DCBE5 435 850           6 178.8 235 034             (Dominated)
DCBE5 448 356           6 173.0 249 784             (Dominated)
COL3 474 893           6 187.5 281 257                 7 487 245
DCBE3 499 560           6 178.5 284 941             (Dominated)
COL, colonoscopy; SIG, sigmoidoscopy; DCBE, double contrast barium enema; FOBT, fecal occult blood test. Current level of colonoscopy cost in Korea is about
53 000 won. 1Exchange rate: 1 200 Korean won for one US dollar. 2National Health Insurance of Korea. 3Incremental CE ratio (won/year) = incremental cost per
person/incremental days of life gained×365 d. 4Dominated strategy is a strategy that is more or equally costly and less effective than a competing strategy.
5Extended dominated: Extended dominated strategy is a strategy which is less effective and had a higher ICER than another strategy.
Park SM et al. Economic strategies to improve colorectal cancer screening compliance     1591
there are only a few medical endoscopists available to
undertake COL in Korea. Korean physicians insist that they
are not willing to contribute to increase in CRC screening
rate because of low reimbursement of COL[25]. Some
surveys indicate that strong recommendation from the
physician is highly correlated with patient participation in
CRC screening[27]. Therefore, raising reimbursement rate
for CRC screening to physicians can be effective in changing
their behavior, which will eventually improve compliance
rate. Our model shows that when the reimbursement for
COL increases up to 85 000 (Korean) won, which is 60%
higher than the current level, along with NHI’s 50%
coverage of screening cost, COL every 10 years or 5 years
not only has lower total medical cost and lower financial
burden on the NHI, but also improves lifetime expectancy
than FOBT annually (Table 4). In addition, the total medical
cost of COL every 10 years was lower than that of no
screening in Korea. More investment in CRC screening is
ideal because it reduces the cost of conventional treatment
and extends life expectancy. Health policy makers should
understand the need to train medical, and possibly even
non-medical, personnel to perform endoscopy and to find
an effective policy to lead physicians to perform
colonoscopy[26].
Our analysis has several limitations. In the design of the
model, we tried to reduce the complex natural history of
CRC to a few essential states and to avoid assumptions on
treatments for which little or no published data existed. For
instance, we assumed that all cancers arose from polyps.
And we used data from western countries if there were no
published data available in Asia. There were possible
differences between the races. Finally, we calculated only
the direct costs and did not take into account the impact of
CRC and screening on indirect costs.
In our conclusion, economic strategies for promoting
screening compliance can be accompanied by expanding
insurance coverage by the NHI and by increasing
reimbursement for CRC screening to providers. And COL
every 10 years is a cost-effective and cost saving screening
strategy for CRC in Korea.
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